欢迎来到OAJRC平台!

期刊目次

加入编委

期刊订阅

添加您的邮件地址以接收即将发行期刊数据:

Open Access Article

International Journal of Medicine and Data. 2022; 6: (1) ; 97-100 ; DOI: 10.12208/ j.ijmd.20220025.

Efficacy evaluation of tofacitinib combined with methotrexate in the treatment of refractoryrheumatoid arthritis
托法替布联合甲氨蝶呤治疗难治性类风湿关节炎疗效评价

作者: 王明杰*, 张艳

衡水市人民医院 河北衡水

*通讯作者: 王明杰,单位:衡水市人民医院 河北衡水;

发布时间: 2022-04-26 总浏览量: 62

摘要

目的 分析难治性类风湿关节炎患者应用托法替布联合甲氨蝶呤的治疗效果。方法 选择我院收治的200例难治性类风湿关节炎患者作为研究对象,选取时间为2019年11月至2021年11月,按随机数字表法随机均分为参照组和治疗组(每组100例),前者给予来氟米特联合甲氨蝶呤(与开题方案相差较多)治疗,后者给予托法替布联合甲氨蝶呤治疗,比较两组健康评定量表(HAQ)评分、视觉模拟(VAS)评分、类风湿因子以及C-反应蛋白水平、ACR病情改善、DAS28评分、SHARP评分。结果 较参照组,治疗组HAQ评分、VAS评分、类风湿因子、C-反应蛋白水平、不良反应发生率、肿胀及压痛关节数更低(P<0.05)。治疗组ACR病情改善明显优于参照组(P<0.05),3个月、6个月DAS28评分明显较低(P<0.05)。治疗组3个月、6个月DAS28评分明显低于参照组,差异有统计学意义(P<0.05)。两组1个月DAS28评分比较、1个月、3个月、6个月SHARP评分比较,差异无统计学意义(P>0.05)。结论 托法替布联合甲氨蝶呤治疗难治性类风湿关节炎效果不错,值得在临床中提倡使用。

关键词: 难治性类风湿关节炎;托法替布;甲氨蝶呤

Abstract

Objective To analyze the therapeutic effect of tofacitinib combined with methotrexate in patients with refractory rheumatoid arthritis.
Methods 200 patients with refractory rheumatoid arthritis admitted to our hospital were selected as the research objects, and the selection time was from November 2019 to November 2021, and they were randomly divided into the reference group and the treatment group (each group) according to the random number table method. group of 100 cases), the former was treated with leflunomide combined with methotrexate (which was much different from the prescribed plan), and the latter was treated with tofacitinib combined with methotrexate. The health assessment scale (HAQ) of the two groups was compared Score, visual analogue (VAS) score, rheumatoid factor and C-reactive protein levels, ACR disease improvement, DAS28 score, SHARP score.
Results Compared with the reference group, the treatment group had lower HAQ score, VAS score, rheumatoid factor, C-reactive protein level, incidence of adverse reactions, swelling and tender joints (P<0.05). The improvement of ACR in the treatment group was significantly better than that in the control group (P<0.05), and the DAS28 score at 3 months and 6 months was significantly lower (P<0.05). The DAS28 score of the treatment group at 3 months and 6 months was significantly lower than that of the reference group, and the difference was statistically significant (P<0.05). There was no significant difference in the DAS28 score at 1 month, and the SHARP score at 1 month, 3 months, and 6 months between the two groups (P>0.05).
Conclusion   Tofacitinib combined with methotrexate has a good effect in the treatment of refractory rheumatoid arthritis, and it is worth promoting in clinical practice.

Key words: Refractory rheumatoid arthritis; Tofacitinib; Methotrexate

参考文献 References

[1] 李荣平,陈琥,谷晓晶,郭迪斌,王飙.托法替布治疗难治性类风湿关节炎的临床研究[J].药品评价,2021,18(7):428-430.

[2] 中华医学会风湿病学分会. 类风湿关节炎诊治指南(草案)[J]. 中华风湿病学杂志, 2003, 17(4):250-254.

[3] 高乐女, 钟兵, 陈雪猛,等. 托法替布治疗中重度类风湿关节炎的疗效及安全性分析[J]. 临床合理用药杂志 2019,12(13):29-31.

[4] 王进军,黄梦,易敏,等.259例类风湿性关节炎患者用药分析[J].巴楚医学,2020,3(04):53-57.

[5] 李志儒,王志太.来氟米特与甲氨蝶呤对难治性类风湿关节炎的临床作用[J].北方药学,2017,14(10):99-100.

[6] 李艳琴,孙强.来氟米特联合甲氨蝶呤治疗类风湿关节炎患者的疗效及对血清生长因子的影响[J].实用临床医药杂志,2020,24(21):108-111.

[7] 韦隽,陈庆云.托法替布联合来氟米特治疗类风湿性关节炎疗效分析[J].临床医药文献电子杂志,2020,7(47):159-160.

[8] 陈春燕, 周华俊, 周宇一,等. 托法替尼联合甲氨蝶呤在类风湿性关节炎合并高危因素患者中的应用价值[J]. 现代实用医学, 2019,31(12):1623-1625.

[9] 李嘉琪,葛卫红,朱怀军,等.托法替尼对类风湿关节炎患者肝酶改变的系统评价[J].中华风湿病学杂志,2017,21(6):392-397.

引用本文

王明杰, 张艳 托法替布联合甲氨蝶呤治疗难治性类风湿关节炎疗效评价[J]. 国际医学与数据杂志, 2022; 6: (1) : 97-100.